Leukemia Therapeutics Market Growth Accelerates: Strategic Forecast Predicts $25.34 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

What Will the Leukemia Therapeutics Industry Market Size Be by 2025?
The market size of leukemia therapeutics has been expanding robustly over the past few years. It is projected to increase from $17.57 billion in 2024 to $18.67 billion in 2025, at a compound annual growth rate (CAGR) of 6.3%. This growth during the historical period is due to factors such as the rise in the elderly population, advancements in diagnostics resulting in early identification of leukemia, increasing occurrences of leukemia, elevated investment in research and development, and the broadening of personalized medicine methodologies.

What's the Long-Term Growth Forecast for the Leukemia Therapeutics Market Size Through 2029?
The market size for leukemia therapeutics is forecasted to witness significant growth in the upcoming years, reaching "$25.34 billion in 2029" with a compound annual growth rate (CAGR) of 7.9%. This growth in the projection period is due to the introduction of new immunotherapies for leukemia, heightened focus on precise medicine for treating leukemia, broadening of the applications of existing leukemia drugs, growing acceptance of gene therapies, and advancements in supportive care for patients suffering from leukemia. Key trends throughout the forecast period include the incorporation of biomarker-driven methods, the emergence of combination therapies for improved effectiveness, a focus on monitoring minimal residual disease, the rise in the use of car-t cell therapies, and investigation into targeted therapies depending on leukemia subtypes.

View the full report here:
https://www.thebusinessresearchcompany.com/report/leukemia-therapeutics-global-market-report

What Are the Key Growth Drivers Fueling the Leukemia Therapeutics Market Expansion?
The leukemia therapeutics market is experiencing growth due to the increasing prevalence of leukemia, a type of blood cancer originating from the bone marrow resulting in uncontrolled blood cell growth. The expansion of medical treatment's reach for leukemia patients globally and the enhancement in the array of treatment choices play significant roles in fuelling this demand. A forecast from the American Cancer Society, a health organization based in the US, stated in a January 2023 report that approximately 59,610 new cases of all types of leukemia are expected, along with around 23,710 deaths from all types of leukemia in the U.S in 2023. Additionally, an estimated new cases of acute myeloid leukemia (AML) will be about 20,380 and roughly 11,310 AML-related deaths are predicted in the same year. These increasing instances of leukemia are a key factor in propelling the leukemia therapeutics market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=6358&type=smp

What Trends Will Shape the Leukemia Therapeutics Market Through 2029 and Beyond?
Leading firms in the leukemia therapeutics market are employing a strategic partnership strategy to aid in the debut and commercialization of their inaugural advanced cancer treatment within the United States. This Strategic cooperation entails businesses utilizing each other's abilities and assets to accomplish mutual victories and achievements. One such example is in February 2023, when Xspray Pharma AB, a biotech firm based in Sweden, joined forces with EVERSANA, an American entity offering commercial services to the life sciences sector. The collaboration's goal is to expedite the American debut and market penetration of the company's first groundbreaking cancer treatment, Dasynoc, used for chronic myeloid leukemia (CML) and acute lymphoblastic leukemia (ALL). Xspray Pharma will retain monetary and strategic management, while giving EVERSANA exclusive commercialization rights to back the Dasynoc introduction, projected for the latter half of 2023.

How Is the Leukemia Therapeutics Market Segmented?
The leukemia therapeutics market covered in this report is segmented -

1) By Treatment Type: Chemotherapy, Immunotherapy, Targeted Therapy, Other Treatments
2) By Type Of Leukemia: Acute Lymphocytic Leukemia, Acute Myeloid Leukemia, Chronic Lymphocytic Leukemia, Chronic Myeloid Leukemia, Other Type Of Leukemia
3) By Molecule Type: Small Molecules, Biologics
4) By End-Users: Hospitals, Homecare, Specialty Clinics, Other End-Users

Subsegments:
1) By Chemotherapy: Alkylating Agents, Antimetabolites, Plant Alkaloids, Corticosteroids
2) By Immunotherapy: Monoclonal Antibodies, CAR T-Cell Therapy, Immune Checkpoint Inhibitors, Vaccines
3) By Targeted Therapy: Tyrosine Kinase Inhibitors (TKIs), BCL-2 Inhibitors, IDH Inhibitors, Other Targeted Agents
4) By Other Treatments: Radiation Therapy, Stem Cell Transplantation, Supportive Care Treatments

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=6358&type=smp

Which Companies Are Leading the Charge in Leukemia Therapeutics Market Innovation?
Major companies operating in the leukemia therapeutics market include Novartis International AG, AbbVie Inc., Bristol Myers Squibb Company, F. Hoffmann-La Roche AG, Sanofi S. A., Agios Pharmaceuticals, Amgen Inc., Argenx SE, Astellas Pharma Inc., BioLineRx Ltd., Cellerant Therapeutics Inc., Daiichi Sankyo Company Limited, Forma Therapeutics Inc., Gilead Sciences Inc., Incyte Corporation, Jazz Pharmaceuticals plc, Johnson & Johnson, Mirati Therapeutics Inc., Molecular Templates Inc., Ono Pharmaceutical Co. Ltd., Pfizer Inc., Seattle Genetics Inc., Stemline Therapeutics Inc., Sunesis Pharmaceuticals Inc., Takeda Pharmaceutical Company Limited, TG Therapeutics Inc., Allogene Therapeutics Inc., Blueprint Medicines Corporation, Karyopharm Therapeutics Inc., Verastem Oncology Inc.

Which Regions Are Leading the Global Leukemia Therapeutics Market in Revenue?
North America was the largest region in the leukemia therapeutics market in 2024.Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the leukemia therapeutics market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6358

This Report Supports:
1.Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2.Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3.Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4.Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Saumya Sahey
Europe: +44 7882 955267,
Asia: +44 7882 955267 & +91 8897263534,
Americas: +1 310-496-7795
Email: saumyas@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.